# Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL

> **NCT05557110** · PHASE2 · COMPLETED · sponsor: **Chen Suning** · enrollment: 35 (actual)

## Conditions studied

- B Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT05557110
- **Lead sponsor:** Chen Suning
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-08
- **Primary completion:** 2024-01-05
- **Final completion:** 2024-03-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05557110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05557110, "Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05557110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*